<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38827835</PMID><DateRevised><Year>2024</Year><Month>06</Month><Day>04</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2532-8689</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>2</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Le infezioni in medicina</Title><ISOAbbreviation>Infez Med</ISOAbbreviation></Journal><ArticleTitle>The prevalence of long COVID-19 syndrome in hospitalized patients with COVID-19 pneumonia.</ArticleTitle><Pagination><StartPage>202</StartPage><EndPage>212</EndPage><MedlinePgn>202-212</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.53854/liim-3202-8</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Long COVID affects millions of individuals worldwide with a wide range of persistent symptoms. Pathogenesis, prevalence and clinical approach of this syndrome remain not well characterized.The aim of the study is the estimation of prevalence of long-COVID and identification of possible risk factors.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="UNASSIGNED">This is an observational prospective study including COVID-19 patients hospitalized at the Department of Infectious Diseases of the University General Hospital of Alexandroupolis (Greece). Eligible COVID-19 patients were interviewed and examined 6, 12 and 18 months after COVID-19 symptoms onset and hospital discharge in order to evaluate the prevalence and consequences of long-COVID symptoms.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total number of 995 patients were included. The median age at discharge was 55 years and 53% of patients were retired. The majority was males (57%). Vaccination against SARS-CoV-2 was completed in 52% (n=517) COVID-19 patients. More than 40% of COVID-19 patients had at least one symptom at 18 months after hospitalization. Intravenous antiviral 0treatment with remdesivir and complete vaccination status were found to lead to lower rates of Long-COVID.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">More studies in larger patient cohorts are needed in order to identify the underlying biological mechanisms of long-COVID and create effective interventions for prevention and treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Petrakis</LastName><ForeName>Vasileios</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, 2 University Department of Internal Medicine, University General Hospital Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rafailidis</LastName><ForeName>Petros</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, 2 University Department of Internal Medicine, University General Hospital Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terzi</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, 2 University Department of Internal Medicine, University General Hospital Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dragoumani</LastName><ForeName>Ioulia</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, 2 University Department of Internal Medicine, University General Hospital Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markatou</LastName><ForeName>Filothei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, 2 University Department of Internal Medicine, University General Hospital Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papanas</LastName><ForeName>Nikolaos</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, 2 University Department of Internal Medicine, University General Hospital Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vradelis</LastName><ForeName>Stergios</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, 2 University Department of Internal Medicine, University General Hospital Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gouveri</LastName><ForeName>Evanthia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, 2 University Department of Internal Medicine, University General Hospital Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panopoulou</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University Laboratory Department, University General Hospital Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papazoglou</LastName><ForeName>Dimitrios</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, 2 University Department of Internal Medicine, University General Hospital Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Periklis</LastName><ForeName>Panagopoulos</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, 2 University Department of Internal Medicine, University General Hospital Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Infez Med</MedlineTA><NlmUniqueID>9613961</NlmUniqueID><ISSNLinking>1124-9390</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Conflicts of interest: The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>3</Day><Hour>4</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38827835</ArticleId><ArticleId IdType="pmc">PMC11142409</ArticleId><ArticleId IdType="doi">10.53854/liim-3202-8</ArticleId><ArticleId IdType="pii">1124-9390_32_2_2024_202-212</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization.  [Access: 9th December 2023].  
 https://covid19.who.int/
</Citation></Reference><Reference><Citation>Lai CC, Liu YH, Wang CY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect. 2020;53:404&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128959</ArticleId><ArticleId IdType="pubmed">32173241</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin KY, Wu PY, Liu WD, et al. Effectiveness of COVID-19 vaccination among people living with HIV during a COVID-19 outbreak. J Microbiol Immunol Infect. 2022;55:535&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9069984</ArticleId><ArticleId IdType="pubmed">35577735</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CC, Chao CM, Hsueh PR. Clinical efficacy of antiviral agents against coronavirus disease 2019: a systematic review of randomized controlled trials. J Microbiol Immunol Infect. 2021;54:767&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233451</ArticleId><ArticleId IdType="pubmed">34253490</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention.  [Access: 9th December 2023].  Available at:  https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.</Citation></Reference><Reference><Citation>Altmann DM, Whettlock EM, Liu S, et al. The immunology of long COVID. Nat Rev Immunol. 2023;l 23:618&#x2013;634.</Citation><ArticleIdList><ArticleId IdType="pubmed">37433988</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9(2):129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832375</ArticleId><ArticleId IdType="pubmed">33453162</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund LC, Hallas J, Nielsen H, et al. Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. Lancet Infect Dis. 2021;21(10):1373&#x2013;1382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8110209</ArticleId><ArticleId IdType="pubmed">33984263</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B, Sudry T, Flaks-Manov N, et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ. 2023;380:e072529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie CE, Lowe DJ, McAuley A, et al. Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study. Nat Commun. 2022;13(1):5663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9556711</ArticleId><ArticleId IdType="pubmed">36224173</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine. 2022;55:101762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Staffolani S, Iencinella V, Cimatti M, et al. Long COVID-19 syndrome as a fourth phase of SARS-CoV-2 infection. Infez Med. 2022;30(1):22&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8929740</ArticleId><ArticleId IdType="pubmed">35350258</ArticleId></ArticleIdList></Reference><Reference><Citation>National Guidelines for Vaccination against SARS-CoV-2. Vol. 2022. National Public Health Organisation; 2021.  [Access: 23rd March 2024].  
 https://eody.gov.gr/en/
</Citation></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open. 2021;4(5):e2111417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res. 2000;48(6):555&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pubmed">11033374</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakalidou D, Skordilis EK, Giannopoulos S, et al. Validity and reliability of the FSS in Greek MS patients. Springerplus. 2013;2(1):304.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710409</ArticleId><ArticleId IdType="pubmed">23888275</ArticleId></ArticleIdList></Reference><Reference><Citation>Bougia MK, Oikonomou NT, Ntafouli M, et al. AB023. Investigation of the reliability of the Medical Outcomes Study (MOS) Sleep Scale in Greek patients with sleep-related breathing disorders. Ann Transl Med. 2016;4(22):AB023.</Citation></Reference><Reference><Citation>Michopoulos I, Douzenis A, Kalkavoura C, et al. Hospital Anxiety and Depression Scale (HADS): validation in a Greek general hospital sample. Ann Gen Psychiatry. 2007;7:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2276214</ArticleId><ArticleId IdType="pubmed">18325093</ArticleId></ArticleIdList></Reference><Reference><Citation>Pla&#xe7;ais L, Richier Q, No&#xeb;l N, et al. Immune interventions in COVID-19: a matter of time? Mucosal Immunol. 2022;15(2):198&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8552618</ArticleId><ArticleId IdType="pubmed">34711920</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM Lifelines Corona Research Initiative. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400(10350):452&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Luciano S, et al. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F, Ling S, Lui LMW, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav Immun. 2022;101:93&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Xu E, Bowe B, et al. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen PA, Andersen MP, Gislason G, et al. Return to work after COVID-19 infection - A Danish nationwide registry study. Public Health. 2022;203:116&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786635</ArticleId><ArticleId IdType="pubmed">35038630</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerlind E, Palstam A, Sunnerhagen KS, et al. Patterns and predictors of sick leave after Covid-19 and long Covid in a national Swedish cohort. BMC Publ Health. 2021;21(1):1023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8164957</ArticleId><ArticleId IdType="pubmed">34059034</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe A, Iwagami M, Yasuhara J, et al. Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis. Vaccine. 2023;41(11):1783&#x2013;1790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9905096</ArticleId><ArticleId IdType="pubmed">36774332</ArticleId></ArticleIdList></Reference><Reference><Citation>Zisis SN, Durieux JC, Mouchati C, et al. The Protective Effect of Coronavirus Disease 2019 (COVID-19) vaccination on postacute sequelae of COVID-19: a multicenter study from a large national health research network. Open Forum Infect Dis. 2022;9:ofac228. doi: 10.1093/ofid/ofac228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac228</ArticleId><ArticleId IdType="pmc">PMC9129153</ArticleId><ArticleId IdType="pubmed">35818362</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22:43&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409907</ArticleId><ArticleId IdType="pubmed">34480857</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimellaro A, Addesi D, Cavallo M, et al. Monoclonal antibodies and antivirals against SARS-CoV-2 reduce the risk of long COVID: a retrospective propensity score-matched case&#x2013;control study. Biomedicines. 2022;10:3135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9775930</ArticleId><ArticleId IdType="pubmed">36551891</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>